VJOncology is committed to improving our service to you

ECC 2015 | Biomarker-driven therapies for triple-negative breast cancer

VJOncology is committed to improving our service to you

Giuseppe Curigliano

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter